newsfilter
← Latest News
GlobeNewswire·

Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update

– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date